Gene therapy approach with aav for the treatment of lgmd2b / dysferlinopathy

CL202600053A1Pending Publication Date: 2026-08-21KATE THERAPEUTICS INC

View PDF 0 Cites 0 Cited by

Patent Information

Patent Timeline

10 Jul 2024

Priority

08 Jan 2026

Application

CL202600053

21 Aug 2026

Publication

CL202600053A1

IPC: A61K31/7088; A61K38/17; A61K38/43; A61K48/00; A61P21/00; C07K14/00; C07K14/47; C07K14/705; C12N15/62; C12N15/86; C12N15/864; C12P21/00

CPC: A61P21/00; C12N2800/40; C12N2750/14143; C12N15/86; A01K2217/054; A01K2227/105; A01K2267/0306; A61K48/005

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

The present invention relates to compositions and methods for the treatment of dysferlinopathies.

Need to check novelty before this filing date? Find Prior Art